Singer, Andrew C, Kirchhelle, Claas and Roberts, Adam ORCID: https://orcid.org/0000-0002-0760-3088 (2019) 'Reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial-resistant infections'. F1000Research, Vol 8, Issue 238.
|
Text
3309779a-8d84-4ebe-a18f-8f2f8962246d_18302_-_andrew_singer.pdf - Accepted Version Available under License Creative Commons Attribution. Download (270kB) | Preview |
Abstract
The pipeline for new antibiotics is dry. Despite the creation of public/private initiatives like Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (Carb-X) and the Antimicrobial Resistance (AMR) Centre, the current focus on ‘push-pull’ incentives for the pharmaceutical industry still relies on economic return. We propose a joint, internationally-funded antimicrobial development institute that would fund permanent staff to take on roles previously assigned to pharmaceutical companies. This institute would receive ring-fenced, long-term, core funding from participating countries as well as charities, with the aim to focus on transforming the largely dormant antimicrobial pipeline. Resulting drugs would be sold globally and according to a principle of shared burdens. Our proposed model for antimicrobial development aims to maximise society’s investment, through open science, investment in people, and the sharing of intellectual property.
Item Type: | Article |
---|---|
Subjects: | QS Anatomy > QS 4 General works. Classify here works on regional anatomy QV Pharmacology > QV 38 Drug action. QV Pharmacology > QV 4 General works WB Practice of Medicine > Therapeutics > WB 330 Drug therapy |
Faculty: Department: | Biological Sciences > Department of Tropical Disease Biology |
Digital Object Identifer (DOI): | https://doi.org/10.12688/f1000research.18302.1 |
Depositing User: | Stacy Murtagh |
Date Deposited: | 11 Mar 2019 11:46 |
Last Modified: | 06 Sep 2019 09:34 |
URI: | https://archive.lstmed.ac.uk/id/eprint/10342 |
Statistics
Actions (login required)
Edit Item |